2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2048

Disability in Discretionary Valued Life Activities and Self-Efficacy Explain a Significant Portion of RA Patients’ Global Assessments
Abstract Number: 959

Discoid Lupus Onset and Decrease Risk of Renal Disease in Patients with Systemic Lupus Erythematosus: Data from a Large Latin American Cohort
Abstract Number: 495

Discontinuation of Biologics in Patients with Rheumatoid Arthritis after Achieving Low-Activity Disease Status
Abstract Number: 269

Discontinuation of Concomitant Medication for Enthesitis-Related Arthritis during 52 Weeks of Treatment with Adalimumab
Abstract Number: 1820

Discordance of Hip Pain with Radiographic Hip Osteoarthritis: The Osteoarthritis Initiative
Abstract Number: 1491

Discovery and Characterization of COVA322, a Clinical Stage Bispecific TNF/IL-17A Inhibitor for the Treatment of Inflammatory Diseases
Abstract Number: 1484

Discovery of ARN-4079 – a Potent, Orally Available Dual Target Inhibitor of Janus Kinase 3 (JAK3) and Interleukin-2 Inducible T-Cell Kinase (ITK) for Rheumatoid Arthritis
Abstract Number: 543

Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol
Abstract Number: 1553

Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
Abstract Number: 2755

Disease Activity and Quality of Life in BEHÇET’S Disease: The Role of Patients Reportedoutcomes
Abstract Number: 2571

Disease Activity and Risk of Cardiovascular Disease in Patients with Ankylosing Spondylitis with High and Low Body Mass Index
Abstract Number: 1395

Disease Activity Is Associated with Insulin Resistance in Early Rheumatoid Arthritis
Abstract Number: 2578

Disease Activity Is the Major Determinant of Quality of Life and Physical Function in Patients with Early Axial Spondyloarthritis. Results from the Esperanza Cohort.
Abstract Number: 396

Disease Activity Scoring: Comparing Patient and Physician Global Assessment of Disease Activity in Rheumatoid Arthritis
Abstract Number: 575

Disease Activity Strongly Influences Work Productivity and Physical Health Related Quality of Life in Early Axial Spondyloarthritis: Data from the SPACE-Cohort

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].